Free  Public health under attack, in the US and beyond

Marketing Authorisations

Sparsentan (Filspari°) in immunoglobulin A nephropathy

Recombinant chikungunya vaccine (Vimkunya°)

Inset. Attenuated chikungunya vaccine (Ixchiqº): harm-benefit balance still unfavourable as of mid-2026

Erdafitinib (Balversa°) as second-line treatment in urothelial carcinoma, after immunostimulatory treatment

Peanut protein (Palforzia°) in oral desensitisation from 1 year of age

Editors' opinion. Obstinacy

Ublituximab (Briumvi°) in multiple sclerosis

Dabrafenib (Tafinlar°) + trametinib (Mekinist°) in the adjuvant treatment of certain types of melanoma

Nivolumab (Opdivo°) before and after surgery in certain lung cancers

Nivolumab (Opdivo°) in neoadjuvant treatment in certain lung cancers: longer survival

Carbamazepine oral suspension (Tegretol°) in newborns: contraindicated due to propylene glycol

New dose strength of the originator Eylea° blocks substitution

Adverse Effects

In-utero exposure to lamotrigine: better elucidated consequences

NSAID + oral anticoagulant: 2-fold greater risk of severe bleeding

TNF-alpha inhibitors: multiple sclerosis

Hormonal contraception: stroke and myocardial infarction (continued)

Isotretinoin: sacroiliitis

Alice in Wonderland syndrome: montelukast, methylphenidate, sertraline, aripiprazole, etc.

Outlook

European fines for anti-generic strategies: when will penalties get tougher?

Free  Biotechnologies: proposed European legislation underpinned by a biased approach

Free  Prescrire's finances: 2025 annual report

Masthead

Free  Masthead